header logo image header logo text
Downloads Login
General Information
ZFIN ID: ZDB-PUB-160417-10
INaP selective inhibition reverts precocious inter- and motorneurons hyperexcitability in the Sod1-G93R zebrafish ALS model
Benedetti, L., Ghilardi, A., Rottoli, E., De Maglie, M., Prosperi, L., Perego, C., Baruscotti, M., Bucchi, A., Del Giacco, L., Francolini, M.
Date: 2016
Source: Scientific Reports 6: 24515 (Journal)
Registered Authors: Del Giacco, Luca, Ghilardi, Anna, Prosperi, Laura
Keywords: Amyotrophic lateral sclerosis, Cellular neuroscience
MeSH Terms:
  • Action Potentials/drug effects*
  • Action Potentials/genetics*
  • Amyotrophic Lateral Sclerosis/diagnosis
  • Amyotrophic Lateral Sclerosis/genetics*
  • Animals
  • Animals, Genetically Modified
  • Disease Models, Animal
  • Gene Expression
  • Locomotion
  • Motor Activity/drug effects
  • Motor Neurons/drug effects*
  • Motor Neurons/physiology*
  • Muscles/pathology
  • Mutation
  • Neuromuscular Junction/metabolism
  • Phenotype
  • Phenylglyoxal/analogs & derivatives*
  • Phenylglyoxal/pharmacology
  • Riluzole/pharmacology
  • Spinal Cord/pathology
  • Superoxide Dismutase/genetics*
  • Zebrafish
PubMed: 27079797 Full text @ Sci. Rep.
The pathogenic role of SOD1 mutations in amyotrophic lateral sclerosis (ALS) was investigated using a zebrafish disease model stably expressing the ALS-linked G93R mutation. In addition to the main pathological features of ALS shown by adult fish, we found remarkably precocious alterations in the development of motor nerve circuitry and embryo behavior, and suggest that these alterations are prompted by interneuron and motor neuron hyperexcitability triggered by anomalies in the persistent pacemaker sodium current INaP. The riluzole-induced modulation of INaP reduced spinal neuron excitability, reverted the behavioral phenotypes and improved the deficits in motor nerve circuitry development, thus shedding new light on the use of riluzole in the management of ALS. Our findings provide a valid phenotype-based tool for unbiased in vivo drug screening that can be used to develop new therapies.